GHK-Cu Capsules prices

FROM PEPTIDES CALCULATOR

About GHK-Cu

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide first isolated from human plasma by Loren Pickart in 1973 and released from proteins such as albumin and collagen at sites of injury. The copper is held by the glycine amine, the histidine imidazole and a deprotonated amide nitrogen, which is why the complex is described as a non-toxic copper carrier, and its plasma level is reported to fall from about 200 ng/mL at age 20 to 80 ng/mL by 60. Nearly all human evidence is topical: a 1994 vehicle-controlled gel trial in diabetic foot ulcers, a 2006 post-laser study that found no objective benefit, cosmetic cream studies, and a Phase 2 topical wound-gel trial that began recruiting in 2026. Injected GHK-Cu rests on mouse and pig experiments plus clinic and community practice; it is sold as the cosmetic ingredient Copper tripeptide-1 and as a research chemical, was placed in the FDA's compounding Category 2 in 2023 with its status under review again in 2026, and is not named on the WADA list according to the sources below.

Formula

C14 H22 Cu N6 O4

Molar mass

401.9 g/mol

Amino acids

3

Research evidence described in the source

Limitations noted in the source

• Topical concentration data cannot validate subcutaneous or intramuscular dosing.
• Copper balance, formulation, and peptide degradation affect interpretation.
• A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
• Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.